{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T09:24:48Z","timestamp":1783761888808,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,22]]},"DOI":"10.7759\/cureus.86549","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T19:20:37Z","timestamp":1750620037000},"source":"Crossref","is-referenced-by-count":3,"title":["A Systematic Review on the Efficacy of Bisphosphonates on Osteogenesis Imperfecta"],"prefix":"10.7759","author":[{"given":"Rohan R","family":"Datir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit R","family":"Datir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja R","family":"Datir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Heyrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4055\/cios20060","article-title":"Management of osteogenesis imperfecta: a multidisciplinary comprehensive approach","volume":"12","author":"Cho TJ","year":"2020","unstructured":"Cho TJ, Ko JM, Kim H, Shin HI, Yoo WJ, Shin CH. Management of osteogenesis imperfecta: a multidisciplinary comprehensive approach. Clin Orthop Surg. 2020, 12:417-29. 10.4055\/cios20060","journal-title":"Clin Orthop Surg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/humu.9430","article-title":"Mutation analysis of COL1A1 and COL1A2 in patients diagnosed with osteogenesis imperfecta type I-IV","volume":"27","author":"Pollitt R","year":"2006","unstructured":"Pollitt R, McMahon R, Nunn J, Bamford R, Afifi A, Bishop N, Dalton A. Mutation analysis of COL1A1 and COL1A2 in patients diagnosed with osteogenesis imperfecta type I-IV. Hum Mutat. 2006, 27:716. 10.1002\/humu.9430","journal-title":"Hum Mutat"},{"key":"ref3","article-title":"COL1A1- and COL1A2-related osteogenesis imperfecta","author":"Rodriguez Celin M","year":"2025","unstructured":"Rodriguez Celin M, Steiner RD, Basel D. COL1A1- and COL1A2-related osteogenesis imperfecta. GeneReviews\u00ae [Internet]. Adam MP, Feldman J, Mirzaa GM, et al. (ed): University of Washington, Seattle, Seattle (WA); 2025."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10174","article-title":"Osteogenesis imperfecta: new perspectives from clinical and translational research","volume":"3","author":"Tauer JT","year":"2019","unstructured":"Tauer JT, Robinson ME, Rauch F. Osteogenesis imperfecta: new perspectives from clinical and translational research. JBMR Plus. 2019, 3:e10174. 10.1002\/jbm4.10174","journal-title":"JBMR Plus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake MT","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008, 83:1032-45. 10.4065\/83.9.1032","journal-title":"Mayo Clin Proc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: current status","volume":"12","author":"Roelofs AJ","year":"2006","unstructured":"Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006, 12:6222s-30s. 10.1158\/1078-0432.CCR-06-0843","journal-title":"Clin Cancer Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/ar2681","article-title":"RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro","volume":"11","author":"Sutherland KA","year":"2009","unstructured":"Sutherland KA, Rogers HL, Tosh D, Rogers MJ. RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. Arthritis Res Ther. 2009, 11:R58. 10.1186\/ar2681","journal-title":"Arthritis Res Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2020.612728","article-title":"Phosphonate and bisphosphonate inhibitors of farnesyl pyrophosphate synthases: a structure-guided perspective","volume":"8","author":"Park J","year":"2020","unstructured":"Park J, Pandya VR, Ezekiel SJ, Berghuis AM. Phosphonate and bisphosphonate inhibitors of farnesyl pyrophosphate synthases: a structure-guided perspective. Front Chem. 2020, 8:612728. 10.3389\/fchem.2020.612728","journal-title":"Front Chem"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012098652-1.50180-3","article-title":"Bisphosphonates: mechanisms of action","volume":"19","author":"Fleisch H","year":"1998","unstructured":"Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998, 19:80-100. 10.1016\/B978-012098652-1.50180-3","journal-title":"Endocr Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes DE","year":"1995","unstructured":"Hughes DE, Wright KR, Uy HL, et al.. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995, 10:1478-87. 10.1002\/jbmr.5650101008","journal-title":"J Bone Miner Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.186","article-title":"Bone: effects of bisphosphonates on bone quality components and fracture risk","volume":"8","author":"Warde N","year":"2011","unstructured":"Warde N. Bone: effects of bisphosphonates on bone quality components and fracture risk. Nat Rev Rheumatol. 2011, 8:3. 10.1038\/nrrheum.2011.186","journal-title":"Nat Rev Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118722","article-title":"Bisphosphonates: mechanisms of action","volume":"97","author":"Rodan GA","year":"1996","unstructured":"Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996, 97:2692-96. 10.1172\/JCI118722","journal-title":"J Clin Invest"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald JD","year":"2015","unstructured":"Hald JD, Evangelou E, Langdahl BL, Ralston SH. Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res. 2015, 30:929-33. 10.1002\/jbmr.2410","journal-title":"J Bone Miner Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers R","year":"2004","unstructured":"Sakkers R, Kok D, Engelbert R, et al.. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet. 2004, 363:1427-31. 10.1016\/S0140-6736(04)16101-1","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-006-0399-2","article-title":"Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial","volume":"166","author":"Kok DH","year":"2007","unstructured":"Kok DH, Sakkers RJ, Janse AJ, Pruijs HE, Verbout AJ, Castelein RM, Engelbert RH. Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial. Eur J Pediatr. 2007, 166:1155-61. 10.1007\/s00431-006-0399-2","journal-title":"Eur J Pediatr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward LM","year":"2011","unstructured":"Ward LM, Rauch F, Whyte MP, et al.. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab. 2011, 96:355-64. 10.1210\/jc.2010-0636","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4158\/EP171910.OR","article-title":"Zoledronic acid versus alendronate in the treatment of children with osteogenesis imperfecta: a 2-year clinical study","volume":"24","author":"Lv F","year":"2018","unstructured":"Lv F, Liu Y, Xu X, et al.. Zoledronic acid versus alendronate in the treatment of children with osteogenesis imperfecta: a 2-year clinical study. Endocr Pract. 2018, 24:179-88. 10.4158\/EP171910.OR","journal-title":"Endocr Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1515\/jpem.2005.18.1.43","article-title":"A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta","volume":"18","author":"Dimeglio LA","year":"2005","unstructured":"Dimeglio LA, Ford L, McClintock C, Peacock M. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2005, 18:43-53. 10.1515\/jpem.2005.18.1.43","journal-title":"J Pediatr Endocrinol Metab"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2007.125468","article-title":"Two doses of pamidronate in infants with osteogenesis imperfecta","volume":"93","author":"Senthilnathan S","year":"2008","unstructured":"Senthilnathan S, Walker E, Bishop NJ. Two doses of pamidronate in infants with osteogenesis imperfecta. Arch Dis Child. 2008, 93:398-400. 10.1136\/adc.2007.125468","journal-title":"Arch Dis Child"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-0208","article-title":"GH in combination with bisphosphonate treatment in osteogenesis imperfecta","volume":"163","author":"Antoniazzi F","year":"2010","unstructured":"Antoniazzi F, Monti E, Venturi G, et al.. GH in combination with bisphosphonate treatment in osteogenesis imperfecta. Eur J Endocrinol. 2010, 163:479-87. 10.1530\/EJE-10-0208","journal-title":"Eur J Endocrinol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/01.bpo.0000176162.78980.ed","article-title":"Impact of alendronate on quality of life in children with osteogenesis imperfecta","volume":"25","author":"Seikaly MG","year":"2005","unstructured":"Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D, Browne R, Herring JA. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop. 2005, 25:786-91. 10.1097\/01.bpo.0000176162.78980.ed","journal-title":"J Pediatr Orthop"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.051006","article-title":"Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta","volume":"21","author":"DiMeglio LA","year":"2006","unstructured":"DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res. 2006, 21:132-40. 10.1359\/JBMR.051006","journal-title":"J Bone Miner Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4158\/EP151184.OR","article-title":"The clinical characteristics and efficacy of bisphosphonates in adult patients with osteogenesis imperfecta","volume":"22","author":"Xu XJ","year":"2016","unstructured":"Xu XJ, Ma DD, Lv F, et al.. The clinical characteristics and efficacy of bisphosphonates in adult patients with osteogenesis imperfecta. Endocr Pract. 2016, 22:1267-76. 10.4158\/EP151184.OR","journal-title":"Endocr Pract"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"26","author":"Bishop N","year":"2013","unstructured":"Bishop N, Adami S, Ahmed SF, et al.. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2013, 26:1424-32. 10.1016\/S0140-6736(13)61091-0","journal-title":"Lancet Lond Engl"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.051015","article-title":"Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial","volume":"21","author":"Chevrel G","year":"2006","unstructured":"Chevrel G, Schott AM, Fontanges E, et al.. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res. 2006, 21:300-6. 10.1359\/JBMR.051015","journal-title":"J Bone Miner Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.03.013","article-title":"Early bisphosphonate treatment in infants with severe osteogenesis imperfecta","volume":"149","author":"Antoniazzi F","year":"2006","unstructured":"Antoniazzi F, Zamboni G, Lauriola S, Donadi L, Adami S, Tat\u00f2 L. Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr. 2006, 149:174-9. 10.1016\/j.jpeds.2006.03.013","journal-title":"J Pediatr"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2012-0016","article-title":"Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta","volume":"25","author":"Barros ER","year":"2012","unstructured":"Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2012, 25:485-91. 10.1515\/jpem-2012-0016","journal-title":"J Pediatr Endocrinol Metab"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2054","article-title":"Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I","volume":"90","author":"Ward LM","year":"2005","unstructured":"Ward LM, Denker AE, Porras A, et al.. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab. 2005, 90:4051-6. 10.1210\/jc.2004-2054","journal-title":"J Clin Endocrinol Metab"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.050109","article-title":"Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement","volume":"20","author":"Letocha AD","year":"2005","unstructured":"Letocha AD, Cintas HL, Troendle JF, et al.. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res. 2005, 20:977-86. 10.1359\/JBMR.050109","journal-title":"J Bone Miner Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous neridronate in adults with osteogenesis imperfecta","volume":"18","author":"Adami S","year":"2003","unstructured":"Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, Tat\u00f2 L. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res. 2003, 18:126-30. 10.1359\/jbmr.2003.18.1.126","journal-title":"J Bone Miner Res"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.050312","article-title":"Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta","volume":"20","author":"Gatti D","year":"2005","unstructured":"Gatti D, Viapiana O, Lippolis I, Braga V, Prizzi R, Rossini M, Adami S. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. J Bone Miner Res. 2005, 20:1323-6. 10.1359\/JBMR.050312","journal-title":"J Bone Miner Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.090213","article-title":"Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"24","author":"Rauch F","year":"2009","unstructured":"Rauch F, Munns CF, Land C, Cheung M, Glorieux FH. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res. 2009, 24:1282-9. 10.1359\/jbmr.090213","journal-title":"J Bone Miner Res"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti D","year":"2005","unstructured":"Gatti D, Antoniazzi F, Prizzi R, et al.. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res. 2005, 20:758-63. 10.1359\/JBMR.041232","journal-title":"J Bone Miner Res"},{"key":"ref35","article-title":"Intramuscular neridronate in patients with rheumatoid arthritis using corticosteroids: evaluation of treatment adherence in a randomized, open-label comparison with other bisphosphonates","volume":"84","author":"Muratore M","year":"2013","unstructured":"Muratore M, Quarta E, Quarta L. Intramuscular neridronate in patients with rheumatoid arthritis using corticosteroids: evaluation of treatment adherence in a randomized, open-label comparison with other bisphosphonates. Acta Biomed. 2013, 84:23-9.","journal-title":"Acta Biomed"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.354","article-title":"Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study","volume":"148","author":"Tee SI","year":"2012","unstructured":"Tee SI, Yosipovitch G, Chan YC, et al.. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study. Arch Dermatol. 2012, 148:307-14. 10.1001\/archdermatol.2011.354","journal-title":"Arch Dermatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-009-0149-4","article-title":"Response to zolendronic acid in children with type III osteogenesis imperfecta","volume":"28","author":"Panigrahi I","year":"2010","unstructured":"Panigrahi I, Das RR, Sharda S, Marwaha RK, Khandelwal N. Response to zolendronic acid in children with type III osteogenesis imperfecta. J Bone Miner Metab. 2010, 28:451-5. 10.1007\/s00774-009-0149-4","journal-title":"J Bone Miner Metab"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-017-0236-9","article-title":"Long-term effects of neridronate in adults with osteogenesis imperfecta: an observational three-year Italian study","volume":"100","author":"Viapiana O","year":"2017","unstructured":"Viapiana O, Idolazzi L, Fassio A, et al.. Long-term effects of neridronate in adults with osteogenesis imperfecta: an observational three-year Italian study. Calcif Tissue Int. 2017, 100:341-7. 10.1007\/s00223-017-0236-9","journal-title":"Calcif Tissue Int"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04886-4","article-title":"Patient-reported effectiveness and safety of pamidronate in NSAIDs-refractory chronic recurrent multifocal osteomyelitis in children","volume":"42","author":"Juszczak B","year":"2022","unstructured":"Juszczak B, Su\u0142ko J. Patient-reported effectiveness and safety of pamidronate in NSAIDs-refractory chronic recurrent multifocal osteomyelitis in children. Rheumatol Int. 2022, 42:699-706. 10.1007\/s00296-021-04886-4","journal-title":"Rheumatol Int"},{"key":"ref40","article-title":"Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta","volume":"24","author":"Atta I","year":"2014","unstructured":"Atta I, Iqbal F, Waqar Lone S, Ibrahim M, Naqi Khan Y, Raza J. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta. J Coll Physicians Surg Pak. 2014, 24:653-7.","journal-title":"J Coll Physicians Surg Pak"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.3.353","article-title":"Risedronate: a clinical review","volume":"161","author":"Crandall C","year":"2001","unstructured":"Crandall C. Risedronate: a clinical review. Arch Intern Med. 2001, 161:353-60. 10.1001\/archinte.161.3.353","journal-title":"Arch Intern Med"},{"key":"ref42","unstructured":"Critical Appraisal Tools. Joanna Briggs Institute. (2017). Accessed. Jun 17, 2025: https:\/\/jbi.global\/critical-appraisal-tools."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/340827-a-systematic-review-on-the-efficacy-of-bisphosphonates-on-osteogenesis-imperfecta","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T19:20:39Z","timestamp":1750620039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/340827-a-systematic-review-on-the-efficacy-of-bisphosphonates-on-osteogenesis-imperfecta"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,22]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.86549","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,22]]}}}